Lexicon Pharmaceuticals Inc
NASDAQ:LXRX

Watchlist Manager
Lexicon Pharmaceuticals Inc Logo
Lexicon Pharmaceuticals Inc
NASDAQ:LXRX
Watchlist
Price: 0.74 USD -5.71%
Market Cap: 267.5m USD
Have any thoughts about
Lexicon Pharmaceuticals Inc?
Write Note
Section:
 

Relative Value

The Relative Value of one LXRX stock under the Base Case scenario is 0.56 USD. Compared to the current market price of 0.74 USD, Lexicon Pharmaceuticals Inc is Overvalued by 25%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

LXRX Relative Value
Base Case
0.56 USD
Overvaluation 25%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

51.2
P/S
P/S
Price to Sales
51.2
vs History
50
vs Industry
9
Median 3Y
311.2
Median 5Y
73.1
Industry
7.6
Forward
25
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-3.5
Median 5Y
-3
Industry
22.1
Forward
-1.1
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-3.7
Median 5Y
-3.4
Industry
21.9
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-4.6
Median 5Y
-3.1
Industry
23.4
More Details
1.5
P/B
P/B
Price to Book Value
1.5
vs History
82
vs Industry
37
Median 3Y
3
Median 5Y
3.1
Industry
2.5
More Details
23.9
EV/S
EV/S
Enterprise Value to Sales
23.9
vs History
55
vs Industry
9
Median 3Y
252.7
Median 5Y
54
Industry
7.5
Forward
11
More Details
25.6
EV/GP
EV/GP
Enterprise Value to Gross Profit
25.6
vs History
50
vs Industry
6
Median 3Y
121.6
Median 5Y
41.8
Industry
9.3
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-2.6
Median 5Y
-2.4
Industry
4.2
Forward
-0.5
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-2.6
Median 5Y
-2.4
Industry
4
Forward
-0.6
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-2.9
Median 5Y
-2.6
Industry
5.9
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-2.8
Median 5Y
-2.6
Industry
3.9
More Details
2.6
EV/IC
EV/IC
Enterprise Value to IC
2.6
vs History
68
vs Industry
23
Median 3Y
6.8
Median 5Y
6.7
Industry
4.5
More Details

Multiples Across Competitors

LXRX Competitors Multiples
Lexicon Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Lexicon Pharmaceuticals Inc
NASDAQ:LXRX
283.7m USD 51.2 -1.2 -0.6 -0.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 059 457.3 -180 891 -219 659.2 -217 152.6
US
Abbvie Inc
NYSE:ABBV
316.9B USD 5.7 62.3 15.5 23.8
US
Amgen Inc
NASDAQ:AMGN
141.4B USD 4.3 33.4 16 30.4
US
Gilead Sciences Inc
NASDAQ:GILD
117.3B USD 4.1 933.6 10.3 10.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.8B USD 9.9 -220.6 21.8 22.9
US
Epizyme Inc
F:EPE
94.1B EUR 1 851 -472.3 -514.4 -500.7
AU
CSL Ltd
ASX:CSL
136.4B AUD 5.7 32.1 19.9 24.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.9B USD 5.7 17 15.4 17.1
US
Seagen Inc
F:SGT
39.3B EUR 17.8 -54.7 -58.7 -53
NL
argenx SE
XBRU:ARGX
36.2B EUR 19.4 -136.1 -109.9 -80.1
P/S Multiple
Revenue Growth P/S to Growth
US
Lexicon Pharmaceuticals Inc
NASDAQ:LXRX
Average P/S: 3 460 130.2
51.2
184%
0.3
FR
Pharnext SCA
OTC:PNEXF
38 059 457.3
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.7
6%
1
US
Amgen Inc
NASDAQ:AMGN
4.3
8%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
4.1
3%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.9
10%
1
US
E
Epizyme Inc
F:EPE
1 851
N/A N/A
AU
CSL Ltd
ASX:CSL
5.7
7%
0.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
7%
0.8
US
S
Seagen Inc
F:SGT
17.8
30%
0.6
NL
argenx SE
XBRU:ARGX
19.4
47%
0.4
P/E Multiple
Earnings Growth PEG
US
Lexicon Pharmaceuticals Inc
NASDAQ:LXRX
Average P/E: 215.7
Negative Multiple: -1.2 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -180 891 N/A N/A
US
Abbvie Inc
NYSE:ABBV
62.3
72%
0.9
US
Amgen Inc
NASDAQ:AMGN
33.4
20%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
933.6
21%
44.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -220.6
14%
N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472.3 N/A N/A
AU
CSL Ltd
ASX:CSL
32.1
18%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17
13%
1.3
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -136.1 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Lexicon Pharmaceuticals Inc
NASDAQ:LXRX
Average EV/EBITDA: 16.5
Negative Multiple: -0.6 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 659.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.5
9%
1.7
US
Amgen Inc
NASDAQ:AMGN
16
18%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.3
5%
2.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.8
13%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.4 N/A N/A
AU
CSL Ltd
ASX:CSL
19.9
12%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.4
11%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -109.9 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Lexicon Pharmaceuticals Inc
NASDAQ:LXRX
Average EV/EBIT: 21.6
Negative Multiple: -0.6 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 152.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.8
24%
1
US
Amgen Inc
NASDAQ:AMGN
30.4
24%
1.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.4
10%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.9
13%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -500.7 N/A N/A
AU
CSL Ltd
ASX:CSL
24.8
16%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.1
12%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -80.1 N/A N/A

See Also

Summary
LXRX intrinsic value, competitors valuation, and company profile.
DCF Valuation
LXRX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
LXRX stock valuation using valuation multiples.
Wall Street Estimates
LXRX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
LXRX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 211,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.